Financial analysts and long-term equity forecasting models tracking Viking Therapeutics (VKTX) project a generally optimistic trajectory extending toward 2027, driven by anticipated clinical milestones and pipeline advancements in obesity therapeutics. Consensus twelve-month and multi-year projection algorithms estimate that the stock could trade within an average range of 40 to 46 US dollars per share by the end of 2027, assuming continued positive clinical trial data and favorable regulatory pathways. However, biotechnology valuations remain inherently volatile and sensitive to clinical outcomes and broader market conditions.